We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This tax information and impact note is about the reduction of the dividend allowance.
This report presents the findings of an evaluation of Violence Reduction Units (VRUs) in their fourth year of Home Office funding.
These reports present the findings of an impact feasibility study and process evaluation of Violence Reduction Units (VRUs) in the first year of Home Office funding.
Report on non-fatal overdose monitoring data collected from the unlinked anonymous monitoring survey of HIV, hepatitis B and hepatitis C in people who inject drugs.
This series brings together all documents relating to the UK government’s 10-year drugs strategy.
This review provides an analysis of key elements of successful early interventions to prevent or reduce youth crime or anti-social behaviour.
Find drug safety updates issued by MHRA
Sets out the immediate actions government will be taking in the short term in response to the recommendations made in the independent Pregnancy Loss Review.
First published during the 2022 to 2024 Sunak Conservative government
The findings and recommendations of the national overprescribing review led by Dr Keith Ridge, Chief Pharmaceutical Officer for England.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Product Safety Report for Fabrique par Rodis B.B.Clear Lightening Dark Spot Remover presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).